title: Sublingual versus vaginal route of misoprostol for cervical ripening prior to surgical termination of first trimester abortions.
abstract: BACKGROUND
  Sublingual and vaginal routes of misoprostol have been found to be effective for pharmacological ripening prior to surgical termination of first trimester abortions. We conducted this study to compare the effectiveness and acceptability of sublingual versus vaginal route of misoprostol for cervical priming prior to vacuum aspiration (VA).
  
  
  METHODS
  In this prospective clinical trial, a total of 100 women with period of gestation between 6 and 12 weeks scheduled for day surgery abortion were sequentially allocated into two groups of 50 each. All participating women received 400 microg of misoprostol 3 h prior to VA either by sublingual (self-administered at home) or by vaginal route (inserted by the doctor in hospital) after wetting the tablet with water.
  
  
  RESULTS
  Demographic characteristics of both the groups were comparable. For all periods of gestation, sublingual misoprostol significantly improved cervical dilatation (p<0.001) and reduced the time duration of surgery (p<0.001) compared to vaginal group without increasing the side effects. Mean pain score of the sublingual group was 2.7+/-1.1 as compared to 3.2+/-1.6 of the vaginal group (p=0.57). Misoprostol tablet was found intact in the vagina of three patients and was only partially absorbed amongst five patients at the time of VA.
  
  
  CONCLUSIONS
  Sublingual route is an effective and convenient alternative to vaginal administration of misoprostol for cervical dilatation. It can be conveniently self-administered at home thereby decreasing hospital stay and cost. It also has a good patient acceptability rate.
authors.affiliation: Department of Reproductive Biomedicine, National Institute of Health and Family Welfare, New Mehrauli Road, Munirka, New Delhi 110067, India. pikeesaxena@hotmail.com
authors.forename: Pikee
authors.initials: P
authors.lastname: Saxena
authors.forename: Sudha
authors.initials: S
authors.lastname: Salhan
authors.forename: Nivedita
authors.initials: N
authors.lastname: Sarda
mesh_terms: D000028:Abortion, Induced / Q000379:methods*; D000282:Administration, Intravaginal; D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D020070:Cervical Ripening / Q000187:drug effects*; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage*; D010146:Pain; D010342:Patient Acceptance of Health Care; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D014619:Vacuum Curettage / Q000009:adverse effects
chemical_list: D016595:Misoprostol